MarketCap
Facebook
X
TelegramAnnual report 2021
added 12-23-2023
Burning Rock Biotech Limited Revenue 2011-2026 | BNR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Burning Rock Biotech Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 508 M | 430 M | 382 M | 209 M | 111 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 508 M | 111 M | 328 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
6.32 B | $ 117.5 | 2.1 % | $ 35.7 B |  USA |
 |
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 16.83 | 4.86 % | $ 897 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
622 K | $ 1.45 | 5.84 % | $ 1.93 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
332 M | $ 23.53 | 1.73 % | $ 654 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 178.34 | 1.53 % | $ 8.84 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
Interpace Biosciences
IDXG
|
38.7 M | $ 2.2 | -4.35 % | $ 9.73 M | USA |
 |
Danaher Corporation
DHR
|
24.6 B | $ 195.87 | 3.3 % | $ 140 B | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
4.37 B | $ 126.96 | 4.99 % | $ 20.2 B | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 15.3 | 6.03 % | $ 463 M | USA |
 |
Guardant Health
GH
|
982 M | $ 82.21 | 4.59 % | $ 10.3 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
210 K | $ 2.85 | 5.95 % | $ 92.5 K | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 501.23 | 1.56 % | $ 14.5 B | USA |
 |
Biomerica
BMRA
|
5.31 M | $ 2.08 | -2.8 % | $ 4.78 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 28.55 | 0.87 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 110.37 | 3.33 % | $ 9.1 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 264.18 | 1.25 % | $ 22 B | USA |
 |
Myriad Genetics
MYGN
|
824 M | $ 4.59 | 5.52 % | $ 425 M | USA |
 |
NeoGenomics
NEO
|
727 M | $ 8.0 | 4.03 % | $ 1.02 B | USA |
 |
Neogen Corporation
NEOG
|
895 M | $ 9.14 | -2.97 % | $ 1.98 B | USA |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 81.67 | 1.34 % | $ 5.51 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
Natera
NTRA
|
820 M | $ 201.9 | 4.6 % | $ 19.9 B | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 192.91 | 0.73 % | $ 21.4 B | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 5.19 | 5.06 % | $ 4.08 M | USA |
 |
National Research Corporation
NRC
|
137 M | $ 16.82 | 2.03 % | $ 376 M | USA |
 |
Organovo Holdings
ONVO
|
144 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
5.2 M | - | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
160 M | $ 1.45 | 8.21 % | $ 435 M | USA |
 |
Psychemedics Corporation
PMD
|
22.1 M | - | -1.84 % | $ 15.3 M | USA |